close
Add to watchlist
Threshold Pharmaceuticals Inc (THLD) Healthcare, Biotechnology & Drugs
Threshold Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of drugs targeting the microenvironment of solid tumors for patients living with cancer. Its product line includes TH-302, a product candidate in phase I/II for the potential treatment of patients with cancer; Glufosfamide for the treatment of pancreatic cancer; and 2DG, a phase I product candidate for the treatment of patients with cancer. The company was founded in 2001 and is headquartered in Redwood City, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 6.99 |
| Volume | (mio) 5.42 |
| Volume Avg | (mio) 2.65 |
| 52 Week High | 7.10 |
| 52 Week Low | 1.18 |
| PE | N/A |
| PE (group average) | 39 |
| EPS Year | -0.56 |
| EPS change Q/Q | -21.05% |
| EPS change Q/Q Yr ago | -27.78% |
| EPS change Q/Q next Q est | -64.29% |
| EPS change Y/Y | -86.89% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | -0.14 |
| EPS next Y est | -0.24 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |